bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
187 hedge funds and large institutions have $1.71B invested in bluebird bio in 2016 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 81 increasing their positions, 48 reducing their positions, and 38 closing their positions.
69% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 48
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
8% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 38
3% less funds holding
Funds holding: 193 → 187 (-6)
32% less capital invested
Capital invested by funds: $2.53B → $1.71B (-$819M)
46% less call options, than puts
Call options by funds: $16.8M | Put options by funds: $31M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$57M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$18.6M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$11.9M |
| 4 |
State Street
Boston,
Massachusetts
|
+$11.7M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$11.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$42.9M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$34.8M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$18.6M |
| 4 |
State of Tennessee, Department of Treasury
Nashville,
Tennessee
|
-$12.3M |
| 5 |
Capital Fund Management (CFM)
Paris,
France
|
-$12.3M |
BLUE Hedge Fund Activity: Q1 2016 in Review
187 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q1 2016, worth a combined $1.71B — down 32% from $2.53B a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of BLUE and 35 opened new positions — a net loss of 3 holders — while 48 trimmed existing stakes and 81 added.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $57M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $42.9M sold.
- 187 institutional investors held bluebird bio (BLUE) as of Q1 2016, down from 193 in Q4 2015.
- Funds reported $1.71B of bluebird bio stock for Q1 2016, down 32% quarter-over-quarter.
- 35 funds opened new bluebird bio positions in Q1 2016 and 38 closed out, a net change of -3 holders.
- The largest bluebird bio buyer in Q1 2016 was Wellington Management Group, an estimated $57M added.
- The largest bluebird bio seller in Q1 2016 was PFM Health Sciences, an estimated $42.9M sold.
Based on aggregated 13F filings for Q1 2016.